Los Angeles Capital Management
IBRX icon

Los Angeles Capital Management’s ImmunityBio IBRX Stock Holding History

Los Angeles Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.1K Buy
3,550
+258
+8% +$1.95K ﹤0.01% 1639
2026
Q1 		$25.3K Sell
3,292
-128,956
-98% -$883K ﹤0.01% 1678
2025
Q4 		$312K Buy
+132,248
New +$300K ﹤0.01% 1080
2022
Q2 		– Sell
-64,030
Closed -$359K – 1385
2022
Q1 		$359K Hold
64,030
– – ﹤0.01% 1171
2021
Q4 		$389K Buy
+64,030
New +$481K ﹤0.01% 1124

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Los Angeles Capital Management's IBRX Position: Q2 2026 in Review

Los Angeles Capital Management increased its ImmunityBio (IBRX) stake by 7.8% in Q2 2026, buying an estimated $1.95K and bringing the position to 3,550 shares worth $31.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Los Angeles Capital Management first reported a position in IBRX in Q4 2021 and has held it in 5 quarters since. The position peaked at $389K in Q4 2021. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Los Angeles Capital Management held 3,550 shares of ImmunityBio worth $31.1K as of Q2 2026.
  • Los Angeles Capital Management bought 258 ImmunityBio shares in Q2 2026, an estimated $1.95K.
  • ImmunityBio made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1639 holding.
  • Los Angeles Capital Management first reported a position in ImmunityBio in Q4 2021 and has held it in 5 quarters since.
  • Los Angeles Capital Management's ImmunityBio position peaked at $389K in Q4 2021.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.